NCT02032771已完成不适用
Impact of M22 Synergistic Sequential Treatment (SST) Using Intense Pulsed Light and Fractional Non-ablative Photothermolysis on Skin Texture
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 33
- 试验地点
- 3
- 主要终点
- Percentage of Participants with ≥ 50% improvement in Fitzpatrick Elastosis Scale (FES)
研究概览
简要总结
Up to 40 healthy subjects at 2 sites, age 30-65 year old with Fitzpatrick-Elastosis score of 3-6 and mild to moderate age/sun-related facial pigmentation that wish to improve their facial skin appearance.
Hypothesis: The SST will improve the appearance of the wrinkles/elastosis and/or pigmentation by at least 1 on the FES scale or ≥50% in category scale at 3 months follow-ups in at least 50% of the study population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Able to read, understand and provide written Informed Consent;
- •Healthy adult, male or female, 30-65 years of age with Fitzpatrick-Goldman skin type I-V;
- •Having suitable facial areas with wrinkles Fitzpatrick-Goldman Wrinkle and Elastosis Score of 3-6 to be treated;
- •Having suitable facial areas with mild to moderate age/sun-related facial pigmentation
- •Able and willing to comply with the treatment/follow-up schedule and requirements;
- •Women of child-bearing age are required to be using a reliable method of birth control (such as an intrauterine device, birth control pills, condom with spermicidal, Nova ring, partner with vasectomy or abstinence) at least 3 months prior to enrollment and throughout the course of the study.
排除标准
- •Skin type VI
- •Pregnant, intending to become pregnant during the course of study, less than 3 months postpartum or less than 6 weeks after completion of breastfeeding
- •Heavy smoker (>1 pack of cigarettes a day)
- •Unable or unlikely to refrain from tanning, including the use of tanning booths, during the course of the study
- •Use of photosensitive medication for which light exposure is contraindicated.
- •Use of oral isotretinoin (Accutane®) within 3 months of initial treatment or during the course of the study. Note: skin must regain its normal degree of moisture prior to treatment.
- •Having indurate acne in treated area.
- •Any dermal/epidermal damage or disorder, mainly vascular or textural lesions, in treated area
- •Prior treatment, such as chemical peel (especially phenol based) or dermabrasion, in treated area within 3 months of initial treatment or during the course of the study;
- •Prior skin laser/light or another device treatment in treated area within 6 months of initial treatment or during the course of the study
- •Prior use of collagen, fat injections or other methods of skin augmentation (enhancement with injected or implanted material) in treated area within 12 months of initial treatment or during the course of the study. Treatment may not be performed at all over permanent dermal implants
- •Prior use of Botox in treatment area within 6 months
- •Prior ablative resurfacing procedure or face lift in treated area with laser or other devices within 12 months of initial treatment or during the course of the study
- •Any other surgery in treated area within 9 months of initial treatment or during the course of the study.
- •Participation in a study of another investigational device or drug involving the same anatomical site within 3 months prior to enrollment or during this evaluation, or if not involving the same anatomical site, as per the Investigator's discretion
- •History of keloid or any other type of hypertrophic scar formation or poor wound healing in a previously injured skin area
- •Showing symptoms of hormonal disorders, as per the Investigator's discretion (such as Melasma, Chloasma)
- •Concurrent inflammatory skin conditions, Open laceration or abrasion of any sort on area to be treated during the course of treatment
- •Active Herpes Simplex at the time of treatment or having experienced more than three episodes of Herpes Simplex eruption within a year of study enrollment;
- •Multiple dysplastic nevi in area to be treated
- •Having a bleeding disorder or taking anticoagulation medications, including heavy use of aspirin, in a manner which does not allow for a minimum 10 day washout period prior to treatment (as per the subject's physician discretion)
- •History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications
- •Having any form of active cancer at the time of enrollment and during the course of the study or history of skin cancer on the face.
- •Pigmented lesion in the treated area that appears cancerous or is not deemed suitable for photo therapy, as determined by a dermatologist.
- •Significant concurrent illness, such as uncontrolled diabetes i.e. any disease state that in the opinion of the Investigator would interfere with the anesthesia, treatment, or healing process;
- •Mentally incompetent, prisoner or evidence of active substance or alcohol abuse
- •Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research study.
- •For subjects undergoing test spots: considerable undesired response consisting of skin hypopigmentation (long term whitening), a scar or pre scar formation, or any response deemed by the Investigator as grounds for exclusion.
- •Allergies to anesthetics.
结局指标
主要结局
Percentage of Participants with ≥ 50% improvement in Fitzpatrick Elastosis Scale (FES)
时间窗: 3 months following 3rd treatment
Skin improvement by Fitzpatrick Elastosis Scale (FES) or category scale at 3 months based on before/after photos
次要结局
- Percentage of Participants with ≥ 50% improvement in Fitzpatrick Elastosis Scale (FES)(1 and 6 months following 3rd treatment)
- Downtime in days(Following treatment- baseline, 4, 8 weeks)
- Subject Comfort using a Pain Visual Analogue Scale (VAS)(Following treatment- baseline, 4, 8 weeks)
- Number of Participants with Adverse Events(Following treatment #1, 2 and 3 and all follow up visits)
- Subject subjective assessment of improvement using categorical improvement scales(Following treatments- 4, 8 weeks and 1, 3 and 6 months follow up)
- Change in erythema/ edema/ purpura and the response intensity(Following treatments- Baseline, 4, 8 weeks)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
不适用
Impact of Synergistic Sequential Treatment (SST)Improvement of Wrinkles/Elastosis as Well as General Skin ToneNCT01940445Lumenis Be Ltd.17
Unknown
不适用
Effect of Temporization on the Peri-implant Soft Tissue of Immediate Implants: Randomized Controlled Clinical TrialDental Restoration, TemporaryNCT03970811Misr International University22
已完成
3 期
Colchicine and Spironolactone in Patients With MI / SYNERGY Stent RegistryST Elevation Myocardial InfarctionNon ST Elevation Myocardial InfarctionNCT03048825Population Health Research Institute7,264
终止
2 期
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With RuxolitinibPrimary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia MyelofibrosisNCT02226172Pfizer21
已完成
2 期
Evaluation of Pemetrexed Combined With Cisplatin and Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung CancerNCT00497315University Hospital, Antwerp30